Skip to main content

Table 6 Frequency of grade 3–4 adverse events in the FEC and PE arms

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Adverse event

FEC arm [cases (%)]

PE arm [cases (%)]

P value

Hematologic

 Neutropenia

9 (5.96)

17 (11.97)

0.031

 Anemia

6 (4.00)

10 (7.04)

0.248

 Thrombocytopenia

5 (3.31)

7 (4.93)

0.485

Non-hematologic

 Nausea

4 (2.64)

4 (2.82)

0.458

 Vomiting

2 (1.32)

3 (2.11)

0.603

 Diarrhea

2 (1.32)

4 (2.82)

0.951

 Constipation

3 (1.99)

4 (2.82)

0.267

 Hair loss

24 (15.79)

28 (19.72)

0.583

 Dermatitis

8 (5.30)

11 (7.75)

0.395

 Febrile

1 (0.66)

1 (0.70)

0.965

 Fatigue

7 (4.64)

10 (7.04)

0.379

 Hand-foot syndrome

6 (3.97)

5 (3.52)

0.913

 Allergy

0 (0.00)

1 (0.70)

0.143

  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen